C-VELVET [COVID-19]
Research type
Research Study
Full title
Convalescent Plasma Donor Vaccine Study. An observational antibody level study.
IRAS ID
296926
Contact name
Lise Estcourt
Contact email
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Since the beginning of the COVID-19 pandemic scientists have been investigating the potential benefits of convalescent plasma in reducing the burden of the disease, in terms of prevention and treatment. A convalescent plasma collection strategy has been rolled out in the UK under the authority of the Department of Health and Social Care. A clinical study is underway to determine changes in antibody levels individuals who have previously donated COVID-19 convalescent plasma (CCP) and have now received at least one dose of a COVID-19 vaccine. These donors are no longer donating convalescent plasma as their virus-neutralising antibody levels aren’t at a high enough level. The study involves attending a fixed donation centre to give a blood sample. A cohort of registered NHSBT convalescent plasma donors will be invited to participate to the study; potential participants will be identified and approached by the NHSBT donor team to provide information. Participants will provide their consent before arranging a blood collection appointment at their local NHSBT donor centre. The aim of the study is to determine whether vaccination can induce adequate antibody levels to facilitate further collection of convalescent plasma.
REC name
West Midlands - Solihull Research Ethics Committee
REC reference
21/WM/0082
Date of REC Opinion
12 Apr 2021
REC opinion
Further Information Favourable Opinion